Patents Examined by Laura Daniel
-
Patent number: 9006435Abstract: LED compounds of the general structure: (B-S-)n-A-(-S-B)m (Structure 1); wherein the rod-like molecular nucleus A having the structure: -Ar(-T-Ar)p- (Structure 2); wherein T includes a diradical.Type: GrantFiled: September 29, 2010Date of Patent: April 14, 2015Assignee: Lomox LimitedInventor: Gene Carl Koch
-
Patent number: 9000150Abstract: The present invention relates to a process for the preparation of pure meropenem trihydrate.Type: GrantFiled: October 21, 2011Date of Patent: April 7, 2015Assignee: Ranbaxy Laboratories LimitedInventors: Prashant Kumar Sharma, Bhupendra Vashishta, Shailendra K. Singh, Neera Tiwari, Subhash Dhar
-
Patent number: 8969362Abstract: The present invention provides an 8-oxoadenine compound having immunomodulating activities such as an interferon inducing activity and useful as an antiviral agent and antiallergic agent, which is represented by the following formula (1): [wherein the ring A represents a 6-10 membered aromatic carbocyclic ring and the like, R represents a halogen atom, an alkyl group and the like, n represents an integer of 0-2, Z1 represents alkylene, X2 represents oxygen atom, sulfur atom, SO2, NR5, CO, CONR5, NR5CO and the like, Y1, Y2 and Y3 represent independently a single bond or an alkylene group, X1 represents oxygen atom, sulfur atom, NR4 (R4 is hydrogen atom or an alkyl group) or a single bond, R2 represents a substituted or unsubstituted alkyl group, R1 represents hydrogen atom, hydroxy group, an alkoxy group, an alkoxycarbonyl group or a haloalkyl group] or its pharmaceutically acceptable salt.Type: GrantFiled: October 21, 2013Date of Patent: March 3, 2015Assignees: AstraZeneca Aktiebolag, Sumitomo Dainippon Pharma Co., Ltd.Inventors: Ayumu Kurimoto, Kazuki Hashimoto, Yoshiaki Isobe, Stephen Brough, Ian Millichip, Hiroki Wada, Roger Bonnert, Thomas Mcinally
-
Patent number: 8952016Abstract: This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. The compound of the invention are represented by one of the following structural formulas: The variables for these structural formulas are described herein. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.Type: GrantFiled: September 1, 2010Date of Patent: February 10, 2015Assignee: Concert Pharmaceuticals, Inc.Inventors: Roger D. Tung, Julie F. Liu, Scott L. Harbeson
-
Patent number: 8946408Abstract: Novel methods for the production of enantiomerically pure (EP) ?-lactams by decomposition of ?-diazo-?-ketoamides using fluorescent light.Type: GrantFiled: March 15, 2010Date of Patent: February 3, 2015Inventors: Yvette S. Vaske, Maximillian E. Mahoney, Joseph P. Konopelski
-
Patent number: 8946296Abstract: The invention relates to compounds of Formula (I): (A?)x-(A)-(B)—(Z)-(L)-C(?O)NH2 or pharmaceutically acceptable salts or solvates thereof, wherein: (A) is heteroaryl or aryl; each (A?), if present, is indepedently chosen from aryl, arylalkoxy, arylalkyl, heterocyclyl, aryloxy, halo, alkoxy, haloalkyl, cycloalkyl, haloalkoxy, and cyano, wherein each (A?) is substituted with 0, 1, 2 or 3 substituents independently chosen from halo, haloalkyl, aryl, arylalkoxy, alkyl, alkoxy, cyano, sulfonyl, sulfinyl, and carboxamide; X is 0, 1, 2, or 3; (B) is a cyclopropyl ring, wherein (A) and (Z) are covalently bonded to different carbon atoms of (B); (Z) is —NH—; and (L) is —(CH2)mCR1,R2—, wherein m is 0, 1, 2, 3, 4, 5, or 6, and wherein R1 and R2 are each independently hydrogen or C1-C6 alkyl; provided that, if (L) is —CH2— or —CH(CH3)—, then X is not 0. The compounds of the invention are useful in the treatment of diseases such as cancer and neurodegenerative diseases.Type: GrantFiled: April 19, 2010Date of Patent: February 3, 2015Assignee: Oryzon Genomics S.A.Inventors: Alberto Ortega Muñoz, Julio Castro-Palomino Laria, Matthew Colin Thor Fyfe
-
Patent number: 8946257Abstract: N-containing heteroaryl derivatives of formula I or II, wherein the meanings for the various substituents are as disclosed in the description. These compounds are useful as JAK, particularly JAK3, kinase inhibitors.Type: GrantFiled: June 28, 2013Date of Patent: February 3, 2015Assignee: Vectura LimitedInventor: Jorge Salas Solana
-
Patent number: 8946243Abstract: The invention relates to compounds and methods for treating or preventing a viral infection, by administering a monophosphorylated prodrug of acyclovir or monophosphorylated derivative of an acyclovir prodrug to a subject suffering from or susceptible (to a viral infection, such as HIV infection.Type: GrantFiled: March 27, 2009Date of Patent: February 3, 2015Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Katholieke Universiteit LeuvenInventors: Leonid Margolis, Jan Balzarini, Christopher McGuigan, Andrea Lisco, Christophe Vanpouille, Marco Derudas
-
Patent number: 8946303Abstract: To maintain physical fitness and health of middle-aged and older persons living in the threshold of the aging society, the present invention provides a fatigue reducing agent which is highly effective for preventing and reducing fatigue, wherein the agent is made of a composition of substances that are very safe so that long-term administration is possible. A composition containing reduced coenzyme Q was found to be effective for preventing and reducing fatigue, including muscle fatigue. Since the fatigue reducing effect of the composition of the present invention is seen not only in young rats but also more pronounced in aged rats, the present invention can provide the fatigue reducing agent which is very useful, especially, for middle-aged and older persons as well as for young people.Type: GrantFiled: January 19, 2004Date of Patent: February 3, 2015Assignee: Kaneka CorporationInventors: Kenji Fujii, Taizo Kawabe, Kazunori Hosoe, Takayoshi Hidaka
-
Patent number: 8937076Abstract: The present invention relates to a crystalline form of entecavir and its process for preparation, and provides a pharmaceutical composition comprising a therapeutically effective amount of the crystalline form of entecavir. Furthermore, the present invention also provides a use of the crystalline form of entecavir in preparation for a medicament for the treatment of hepatitis B viral infections. The present invention is beneficial toe preparations for pharmaceutical formulations and enhancements of its bioavailability.Type: GrantFiled: January 31, 2008Date of Patent: January 20, 2015Assignee: Zhejiang Medicine Co., Ltd. Xinchang Pharaceutical FactoryInventors: Weidong Ye, Jianyong Yuan, Jingjing Nie, Duanjun Xu, Chaotian Chen
-
Patent number: 8927707Abstract: It discloses a process for refining Aztreonam, comprising the steps of 1) treating Aztreonam material with an alkali metal alkoxylate or an alkali earth metal alkoxylate under heating in the presence of a suitable solvent or a mixture of solvents, followed by adjusting the pH value with a suitable acid and cooling down to precipitate Aztreonam, which provides a primary purified Aztreonam; 2) adsorbing Aztreonam with strongly basic ion exchange resin, followed by eluting the resin and collecting the eluate, to provide a secondary purified Aztreonam after concentration under reduced pressure; 3) adjusting the pH value with a suitable acid to allow crystallization, followed by centrifuging and washing the resultant crystals, to provide a tertiary purified Aztreonam after drying. The refined Aztreonam product has a purity of no less than 99.2%, mostly no less than 99.5%, with little residue on ignition and significantly low content of heavy metals.Type: GrantFiled: March 17, 2011Date of Patent: January 6, 2015Assignee: Hainan Lingkang Pharmaceutical Co., Ltd.Inventor: Linggang Tao
-
Patent number: 8927533Abstract: The present invention relates to novel amide compounds of Formula (I), and their use as anti-tumoral and pro-apoptotic agents. The invention includes the use of such compounds in medicine, in relation to cancer disease as well as other diseases where an inhibition of HDAC is responsive, and the pharmaceutical composition containing such compounds.Type: GrantFiled: September 17, 2012Date of Patent: January 6, 2015Assignee: SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A.Inventors: Giuseppe Giannini, Walter Cabri, Gianfranco Battistuzzi, Davide Vignola, Nicola Fanto', Claudio Pisano, Loredana Vesci
-
Patent number: 8916570Abstract: Disclosed are (N)-methanocarba adenine nucleosides of formulas (I)-(V), for example, of formula (V): as highly potent A3 adenosine receptor agonists, pharmaceutical compositions comprising such nucleosides, and a method of use of these nucleosides, wherein R1-R6 are as defined in the specification. These nucleosides exhibit similar selectivities as agonists of the A3 versus the A1 receptor for both human and mouse adenosine receptors, and are contemplated for use in the treatment a number of diseases, for example, inflammation, cardiac ischemia, stroke, asthma, diabetes, and cardiac arrhythmias.Type: GrantFiled: February 10, 2012Date of Patent: December 23, 2014Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Kenneth A. Jacobson, Dilip K. Tosh
-
Patent number: 8901165Abstract: Described are alkoxylated glycerol acetals according to Formulas (Ia) and (Ib) wherein R1 represents a linear or branched, saturated or unsaturated and optionally substituted hydrocarbyl residue comprising 6 to 22 carbon atoms and 0 or 1 to 3 double bonds, a benzyl or furfuryl radical, R2 is selected from hydrogen, an alkyl, alkenyl or hydroxyalkyl group having 6 to 22 carbon atoms or an acyl group having 6 to 22 carbon atoms and 0 or 1 to 3 double bonds, AO represents an ethylene oxide, a propylene oxide, a butylene oxide unit, or their mixtures, and n is an integer of about 1 to about 100.Type: GrantFiled: September 23, 2010Date of Patent: December 2, 2014Assignee: Cognis IP Management GmbHInventors: Ingo Fleute-Schlachter, Sandra Mack, Peter Kempers, Ulrich Schörken, Eckhard Paetzold, Udo Kragl
-
Patent number: 8883773Abstract: A compound of the formula: wherein X is —N?, —CH?, or the like; W is —CH2— or the like; U is —S— or the like; R1 and R2 are each independently hydrogen, halogen, optionally substituted lower alkyl, or the like; Q is a single bond or the like; R3 is hydrogen or the like; Ring A is a 6-membered aromatic heterocyclic group having 1-3 nitrogen atoms; each R4 is independently hydrogen, halogen, or the like; m is an integer from 0 to 2; G is —C(?O)— or the like; D is a single bond, —NH—, or the like; and E is a cyclic quaternary ammonium group, or an ester, a protected compound at the amino on the ring in the 7-side chain, a pharmaceutically acceptable salt, or a solvate thereof.Type: GrantFiled: April 4, 2011Date of Patent: November 11, 2014Assignee: Shionogi & Co., Ltd.Inventors: Kenji Yamawaki, Hideki Sugimoto, Masayuki Sano
-
Patent number: 8877926Abstract: The disclosure relates to a process for the preparation of the enantiomeric forms of 2,3-diaminopropionic acid derivatives of formula I, wherein R1, R2 and R3 are defined as in the disclosure, by racemate resolution. The separation of the racemate into its enantiomers takes place through formation of diastereomeric salts upon addition of an enantiomerically pure auxiliary, and subsequent separation by fractional crystallization.Type: GrantFiled: February 11, 2013Date of Patent: November 4, 2014Assignee: SanofiInventors: Claus-Dieter Graf, Joerg Rieke-Zapp
-
Patent number: 8877803Abstract: The present invention relates to a novel naphtho class of compounds as Stat3 pathway inhibitors and as cancer stem cell inhibitors; to methods of using such compounds to treat cancer; to methods of using such compounds to treat disorders in a mammal related to aberrant Stat3 pathway activity; to pharmaceutical compositions containing such compounds.Type: GrantFiled: September 10, 2008Date of Patent: November 4, 2014Assignee: Boston Biomedical, Inc.Inventors: Zhiwei Jiang, Chiang Jia Li, Wei Li, David Leggett
-
Patent number: 8865891Abstract: The present invention relates to compounds that are substrates for an enzyme, and upon reaction with the enzyme provide a detectable response, such as an optically detectable response. In particular, the compounds have utility in detecting the presence of a ?-lactamase in a sample. In addition to the compounds, methods are disclosed for analyzing a sample for the presence of a ?-lactamase, for example, as an indicator of expression of a nucleic acid sequence including a sequence coding for a ?-lactamase. Kits are disclosed that include the disclosed compounds and additional components, for example, cells, antibodies, a ?-lactamase or instructions for using the components in an assay.Type: GrantFiled: September 13, 2012Date of Patent: October 21, 2014Assignee: Life Technologies CorporationInventors: Schuyler Corry, William Downey, Brian Filanoski, Kyle Gee, Lawrence Greenfield, James Hirsch, Iain Johnson, Aleksey Rukavishnikov
-
Patent number: 8859761Abstract: It discloses a novel process for refining cefamandole nafate, comprising: 1) adsorbing cefamandole nafate with strongly acidic ion exchange resin, followed by eluting the resin and collecting the eluate, to provide a primary purified cefamandole acid after concentration under reduced pressure; 2) neutralizing the primary purified cefamandole acid with an aqueous solution of sodium hydroxide or an aqueous solution of basic salt of sodium, followed by adjusting the pH value and filtrating out the insoluble substances with heating, thereby providing a secondary purified aqueous solution of cefamandole nafate; and 3) adding ethanol in a volume ratio between ethanol and water of 4:6 into the aqueous solution, to allow recrystallization under controlling the temperature, to provide a tertiary purified cefamandole nafate. The refined cefamandole nafate product has a purity of no less than 99.5%, mostly no less than 99.6%, with significantly low content of heavy metals.Type: GrantFiled: March 17, 2011Date of Patent: October 14, 2014Assignee: Hainan Lingkang Pharmaceutical Co., Ltd.Inventor: Linggang Tao
-
Patent number: 8859555Abstract: The invention relates to a compound of Formula (I): (A?)x-(A)-(B)-(Z)-(L)-(D), wherein: (A) is heteroaryl or aryl; each (A?), if present, is independently chosen from aryl, arylalkoxy, arylalkyl, heterocyclyl, aryloxy, halo, alkoxy, haloalkyl, cycloalkyl, haloalkoxy, and cyano, wherein each (A?) is substituted with 0, 1, 2, or 3 substituents independently chosen from halo, haloalkyl, aryl, arylalkoxy, alkyl, alkoxy, cyano, sulfonyl, amido, and sulfinyl; X is 0, 1, 2, or 3; (B) is a cyclopropyl ring, wherein (A) and (Z) are covalently bonded to different carbon atoms of (B); (Z) is —NH—; (L) is chosen from —CH2CH2—, —CH2CH2CH2—, and —CH2CH2CH2CH2—; and (D) is chosen from —N(—R1)-R2, —O—R3, and —S—R3, wherein: R1 and R2 are mutually linked to form a heterocyclic ring together with the nitrogen atom that R1 and R2 are attached to, wherein said heterocyclic ring has 0, 1, 2, or 3 substituents independently chosen from —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)(C1-C6 alkyl), alkyl, halo, cyano, alkoxy, haloalkyl, andType: GrantFiled: April 19, 2010Date of Patent: October 14, 2014Assignee: Oryzon Genomics S.A.Inventors: Alberto Ortega Muñoz, Julio Castro-Palomino Laria, Matthew Colin Thor Fyfe